GEO Starter Kit: Boost Pharma AI Search Visibility with Generative Engine Optimization

The pharmaceutical industry has long operated in a highly controlled digital environment. Clinical content, regulatory review, and brand compliance have defined the parameters of online visibility. Search engine optimization has been the primary lever for digital discoverability, and pharma organizations have invested heavily in ranking for high-value medical queries.

That paradigm is now changing at a pace that demands executive attention.

AI-powered search, anchored by Google's AI Overviews, Microsoft's Copilot Search, ChatGPT Search, and Perplexity, is fundamentally altering how healthcare professionals and patients discover medical information, further accelerated by the rise of Open Evidence ecosystems and machine-readable protocols like WebMCP that enable AI systems to access, interpret, and cite trusted sources more effectively. Within pharma, this shift most acutely affects two critical functions: Medical, which must ensure clinical and scientific content is accurately cited by AI systems; and Commercial, which must manage how brand narratives and product information are represented in AI-generated answers.

Rather than navigating ranked links, users increasingly receive direct, synthesized answers. Search has become an answer engine, and success has shifted from ranking position to inclusion in the answer itself.

For pharmaceutical and life sciences organizations, this is both a risk and a strategic opportunity. AI systems are already surfacing answers about drug mechanisms, treatment protocols, clinical trial results, and patient support options. If pharma brands are not engineered to be cited by these systems, third-party or competitor content fills that gap.

Generative Engine Optimization (GEO) is the strategic discipline that ensures pharmaceutical content is structured, authoritative, and semantically rich enough to be selected, cited, and surfaced by AI systems. It extends traditional SEO for an era where the search interface itself has been redesigned.

This GEO Starter Kit is structured as a practical journey through six progressive stages: understanding the shift underway, defining GEO, recognizing why it matters specifically for pharma, assessing where your organization stands today, building GEO capability through a proven framework, and establishing the measurement infrastructure to track and sustain progress.

2.1 Traditional Search: The SEO-Led Era

For two decades, digital visibility in healthcare and pharma followed a well-established playbook. Organizations competed for keyword rankings, invested in domain authority, acquired backlinks, and built content libraries designed to capture traffic from search engine results pages (SERPs). The fundamental assumption was that visibility meant appearing in the top organic results, and that users would click through to consume brand-controlled content.

2.2 The Emergence of Generative Search

The introduction of Google's AI Overviews in 2024 marked the most significant disruption to this model in a generation. Rather than returning a list of links, AI systems now synthesize information from multiple sources and deliver a direct, conversational answer at the top of the page.

The impact on user behavior has been immediate and measurable. Users no longer need to navigate to a source website when the answer is already present in the search interface. This is the zero-click phenomenon.

2.3 How Search Has Evolved: A Timeline

Search has evolved from indexing information to understanding human intent, and it’s heading toward anticipation.

2.4 Key Paradigm Shifts

The table below captures the core shift in how digital visibility must be understood. Each traditional SEO metric has a GEO-era equivalent that better reflects where commercial value is now created.

Generative Engine Optimization (GEO) is the practice of engineering digital content, information architecture, and brand authority signals to maximize inclusion in AI-generated answers across search engines, large language models, and conversational AI platforms.

Where traditional SEO optimizes for ranking algorithms, GEO optimizes for answer selection. The underlying question shifts from “How do we rank first?” to “How do we become the source the AI cites?”

3.1 The Six Core Dimensions of GEO

4.1 The Healthcare Search Shift

Healthcare search is undergoing a fundamental shift. Nearly 89% of healthcare-related queries now trigger AI-generated overviews, meaning critical information on diseases, drugs, and treatment protocols is often delivered directly within the search experience, before a user ever clicks through to a brand site. At the same time, HCP reliance on AI for clinical workflows is growing rapidly.

4.2 Patient Discovery Journeys

The patient search journey has been fundamentally restructured by AI. About one-third of consumers under age 45 have used online health content to find a doctor within the past two years. If a brand's drug information, patient support resources, or clinical content is not engineered to appear in AI-generated answers, patients may form their understanding of a therapy from competitor content, unverified sources, or incomplete information.

4.3 Risk and Opportunity Matrix

The table below maps the key risks and opportunities GEO creates for pharmaceutical organizations across commercial, medical, and regulatory functions.

Before building a GEO strategy, organizations need an honest assessment of where they currently stand. The barriers to GEO readiness in pharma are structural, not just technical, and they apply differently depending on whether an organization is primarily focused on HCP engagement, patient support, or corporate digital presence.

This section is the self-assessment gateway of the GEO Starter Kit. It defines the unique barriers pharma organizations face, maps the gap between current and GEO-ready states, and provides a maturity model to locate your organization’s starting point.

5.1 Barriers Unique to Pharma

AI Hallucination Risks in Medical Contexts

AI-generated medical answers carry an inherent risk of hallucination. When pharmaceutical content is poorly structured or absent from authoritative off-site sources, AI systems may fill the gap with synthesized content that cannot be verified. This creates both a patient safety risk and reputational exposure.

Regulatory and MLR Compliance Complexities

GEO operates in an environment where AI systems may combine, paraphrase, and contextualize brand content in ways that bypass reviewed materials. Structured data and FAQ content require MLR alignment that most pharma organizations have not yet established as a standard workflow.

Lack of Source Attribution and Provenance Control

Traditional web publishing gives brands clear control over what appears on their owned properties. AI search removes that control. A brand cannot dictate which of its content pages will be cited, in what context, or alongside what other sources. GEO strategy must optimize the quality, accuracy, and structure of all owned content accordingly.

Additional Structural Challenges

5.2 Current State vs GEO-Ready State

5.3 GEO Readiness Maturity Model: Where Does Your Organisation Sit?

Most pharmaceutical organizations currently sit at Stage 1 or early Stage 2. The GEO Starter Kit framework in the next section is designed to accelerate the journey toward Stages 3 and 4. Use this model to locate your organization before engaging with the six-pillar framework.

The following six-pillar framework defines the core dimensions of Generative Engine Optimization (GEO). Together, these pillars form a comprehensive and scalable model for structuring, governing, and optimizing digital presence in an AI-driven discovery landscape. The recommended approach is to assess readiness across each pillar, identify the highest-impact gaps relative to your maturity stage, and build a prioritized program of work accordingly.

Overview

A leading global biopharmaceutical organization undertook a strategic transformation to strengthen its digital visibility in response to the rapid shift toward AI-driven search. The objective was to improve not only search rankings, but also AI interpretability, citation potential, and inclusion in synthesized answers across emerging generative platforms.

Strategic Challenge

As search behavior shifted toward AI-assisted discovery, the organization faced structural gaps that traditional optimization could not address, from limited inclusion in AI-generated answers, to inconsistent semantic structuring, to weakening authority signals across key content areas. A more fundamental transformation was needed.

GEO-Led Transformation Approach

Indegene implemented an integrated GEO strategy spanning answer-led content engineering, semantic and entity optimization, topical authority development, and technical enablement for AI visibility, anchored by a continuous optimization framework to sustain performance over time.

Outcomes and Impact

The GEO-led strategy delivered sustained improvements across both traditional SEO performance and AI visibility metrics, demonstrating the effectiveness of a unified optimization approach:

Strategic Implication

This transformation demonstrates that GEO is not an incremental extension of SEO, but a structural evolution of digital visibility strategy. Organizations that align content, semantics, and technical architecture with how AI systems evaluate information will be best positioned to lead in an AI-first discovery landscape.

8.1 Why Traditional SEO Metrics Are Insufficient

The metrics that have defined digital visibility success for pharmaceutical brands over the past two decades are becoming unreliable indicators of actual AI-era performance. Organic traffic volumes decline even when AI answer inclusion increases. Click-through rates drop even as brand presence in AI answers grows. Traditional metrics must be supplemented with GEO-native KPIs that capture how visibility is created in an AI-first search environment.

8.2 The GEO KPI Framework

9.1 The Next Phase: Agentic and Conversational AI

Beyond static AI Overviews, the next phase of AI search will involve fully conversational and agentic interfaces. With 1 in 3 U.S. consumers (32%) now using AI for health questions, conversational search is rapidly becoming a primary discovery channel. Patients will have extended dialogues with AI health assistants about their conditions and medication management. HCPs will use AI agents to review clinical trial data and compare therapeutic options. These agentic workflows will require GEO strategy that accounts not just for individual query responses, but for multi-turn conversations and autonomous AI research behavior.

9.2 Emerging Trends Pharma Leaders Should Monitor

9.3 Strategic Recommendations for Pharma Leadership

Generative Search Optimization is not a future-state concern for pharmaceutical organizations. It is an immediate competitive reality. AI-generated answers are already shaping the information landscape that HCPs and patients navigate. The question is not whether pharma needs a GEO strategy, it is whether that strategy is being built today or deferred until the visibility gap is too large to recover. This GEO Starter Kit has been designed to help pharmaceutical organizations take the first practical steps on that journey.

Authors

Niko Plaitakis

EVP, Director of Technology and Experience, CultHealth, an Indegene Company

Todd Hoza

SVP, Head of Digital, CultHealth, an Indegene Company

Devashish Satarkar

AVP, Campaign Management, Indegene

Gary Khan

Director, Omnichannel Marketing Operations, Indegene

Related Insights

• Report

  Execute Omnichannel as an Operating Model

• Report

  Paid Media in Pharma

• Report

  Get Started with Congress Social Intelligence